quinazolines has been researched along with Cytomegalic Inclusion Disease in 119 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.84) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (1.68) | 29.6817 |
| 2010's | 50 (42.02) | 24.3611 |
| 2020's | 66 (55.46) | 2.80 |
| Authors | Studies |
|---|---|
| Baldanti, F; Campanini, G; Cassaniti, I; Fratini, A; Girelli, F; Meini, A; Novazzi, F; Palumbo, L; Paolucci, S; Plebani, A; Tebaldi, A | 1 |
| Bloor, AJC; Byrne, J; Carpenter, B; Crea, P; Duncan, N; Errico, G; Gilleece, MH; Hurst, E; Khan, A; Lovell, R; Lozano, S; Marzolini, MAV; Mehra, V; Nicholson, E; Orchard, K; Pagliuca, A; Parker, A; Peggs, KS; Pirrie, J; Publicover, A; Snowden, JA; Tholouli, E; Thomson, KJ | 1 |
| Badshah, C; Cho, CR; Davis, C; Dykstra, K; Fancourt, C; Leavitt, R; Macha, S; Murata, Y; Prohn, M; Sabato, P; Stone, J; Viberg, A | 1 |
| Aaltonen, S; Helanterä, I; Koivuviita, N; Lempinen, M; Ortiz, F | 1 |
| Garg, N; Jorgenson, MR; Kleiboeker, H; Mandelbrot, DA; Odorico, JS; Parajuli, S; Saddler, CM; Smith, JA | 1 |
| Cho, C; Dumke, H; Giralt, S; Han, G; Jakubowski, A; Karantoni, E; Nawar, T; Papanicolaou, G; Perales, MA; Shaffer, B; Stern, A; Su, Y; Tamari, R; Zavras, P | 1 |
| Dadwal, SS; Dickter, JK; Lee, BV; Ross, JA; Tegtmeier, BR; Zain, JM | 1 |
| Bacchus, M; Baker, AW; Berry, H; Eichenberger, EM; Ferrari, A; Kakoullis, SA; Maziarz, EK; Reynolds, JM; Saullo, JL; Snyder, LD; Steinbrink, JM; Wolfe, CR; Zaffiri, L | 1 |
| Alessandrino, EP; Baldanti, F; Bernasconi, P; Binaschi, L; Borsani, O; Caldera, D; Cassinelli, G; Colombo, AA; Ferretti, VV; Gabanti, E; Lilleri, D; Sciarra, R; Zavaglio, F | 1 |
| Alain, S; Beauvais, D; Bénard, N; Brissot, E; Ceballos, P; Chevallier, P; Coiteux, V; Ducastelle-Lepretre, S; Joris, M; Liautard, C; Marçais, A; Nguyen, S; Redjoul, R; Robin, C; Rubio, MT; Thiebaut, A; Turlure, P; Xhaard, A; Yakoub-Agha, I | 1 |
| Babushok, D; Carulli, A; Frey, NV; Freyer, CW; Ganetsky, A; Gier, S; Gill, SI; Hexner, EO; Loren, AW; Luger, SM; Mangan, JK; Martin, ME; McCurdy, SR; Perl, AE; Porter, DL; Pratz, K; Schuster, M; Smith, J; Stadtmauer, EA; Timlin, C | 1 |
| Steininger, C; Weinberger, S | 1 |
| Boelens, JJ; Chan, A; Cirincione, A; Kernan, NA; Kunvarjee, B; Mathew, S; P Daukshus, N; Papanicolaou, GA; Seo, SK; Siver, M | 1 |
| Boivin, G; Goyette, N; Piret, J | 1 |
| Akashi, K; Harada, T; Jinnouchi, F; Kato, K; Kikushige, Y; Kunisaki, Y; Miyamoto, T; Mori, Y; Numata, A; Shima, T; Takenaka, K; Yamauchi, T; Yoshimoto, G | 1 |
| Abboud, C; Abboud, R; Cashen, AF; Crain, M; Gao, F; Liu, LW; Olson, M; Pusic, I; Schroeder, MA; Stockerl-Goldstein, K; Vij, R; Westervelt, P; Yn, A | 1 |
| Fujita, S; Hotta, M; Ichikawa, J; Ishii, K; Ishii, Y; Ito, T; Konishi, A; Nakanishi, T; Nomura, S; Saito, R; Satake, A; Yoshimura, H | 1 |
| Bogiel, T; Czyzewski, K; Debski, R; Dziedzic, M; Jaremek, K; Konieczek, J; Lecka, M; Richert-Przygonska, M; Styczynski, J | 1 |
| Chou, S; Kleiboeker, S | 1 |
| Biernacki, MA; Boeckh, M; Castor, J; Greninger, AL; Jerome, KR; Joncas-Schronce, L; Kim, Y; Martin, PJ; Perchetti, GA; Sandmaier, BM; Ueda Oshima, M; Xie, H; Zamora, D | 1 |
| Haber, B; Limaye, AP | 1 |
| Ahmad, K; Aryal, S; Brown, AW; Chun, J; Cochrane, A; Desai, S; Fregoso, M; Katugaha, SB; King, C; Marinak, L; Nathan, SD; Shlobin, OA | 1 |
| Barker, J; Bhatt, V; DeRespiris, L; Giralt, SA; Griffin, M; Jakubowski, AA; Lau, C; Lin, A; Maloy, M; Papadopoulos, EB; Papanicolaou, GA; Perales, MA; Proli, A; Seo, SK; Shaffer, B; Su, Y | 1 |
| Mori, T | 1 |
| Alsuliman, T; Bazarbachi, A; Beauvais, D; Bonnin, A; Brissot, E; Mear, JB; Souchet, L; Villate, A; Yakoub-Agha, I | 1 |
| Acharya, N; Doan, T; Gonzales, JA; Shantha, JG; Tsui, E | 1 |
| Bar-On, S; Haynes, RK; Lantsberg, D; Laskov, I; Oiknine-Djian, E; Panet, A; Wolf, DG | 1 |
| Abidi, MZ; Bajrovic, V; Benamu, E; Chase, S; Gakhar, N; Gutman, JA; Haverkos, BM; Kaiser, J; MacDonald, J; Miller, M; Purev, E; Sharma, P; Tobin, J; Weinberg, A | 1 |
| Barnard, R; Chou, S; Douglas, CM; Holder, D; Leavitt, R; Levitan, D; Maguire, M; Nickle, D; Strizki, J; Teal, V; van Alewijk, DCJG; van Doorn, LJ; Wan, H | 1 |
| Han, SH; Hong, YM; Jo, H; Jo, JH; Kwon, DE; Lee, KH; Lim, BJ; Min, SY | 1 |
| Badshah, CS; Butterton, JR; Chemaly, RF; Leavitt, RY; Ljungman, PT; Marty, FM; Teal, VL; Wan, H; Yeh, WW | 1 |
| Ferreira, VH; Humar, A; Husain, S; Kumar, D; Phoompoung, P; Tikkanen, J; Viswabandya, A | 1 |
| Alain, S; Bénard, N; Berceanu, A; Ceballos, P; Cordonnier, C; D'Aveni, M; Nguyen-Quoc, S; Pahlavan-Grumel, G; Redjoul, R; Robin, C; Sicre de Fontbrune, F; Thiebaut, A | 1 |
| Acosta, E; Bowlin, T; Brooks, J; Chiang, L; Hussein, I; Kauvar, LM; Kimberlin, D; Leavitt, R; Prichard, M; Whitley, R | 1 |
| Anderson, A; Camargo, J; Komanduri, K; Morris, M; Raja, M; Vazquez, N | 1 |
| Elefant, E; Faure Bardon, V; Guilleminot, T; Lê, MP; Leruez-Ville, M; Peytavin, G; Stirnemann, J; Ville, Y | 1 |
| Alain, S; Berceanu, A; Ducastelle-Lepretre, S; Feghoul, L; Frobert, E; Girault, S; Guerin, E; Hantz, S; Le Goff, J; Lepiller, Q; Michonneau, D; Peytavin, G; Tilloy, V | 1 |
| Brown, JW; Domingo, W; Efron, B; Johnsrud, JJ; Narasimhan, B; Nguyen, IT | 1 |
| Berney, T; Elkrief, L; Kronig, I; Neofytos, D; Van Delden, C | 1 |
| Hosoi, H; Murata, S; Mushino, T; Nishikawa, A; Sonoki, T | 1 |
| Alsumali, A; Chemaly, RF; Graham, J; Jiang, Y; Merchant, S; Miles, L; Schelfhout, J; Tang, Y; Yang, J | 1 |
| Burgmann, H; Fisecker, L; Schubert, L; Steininger, C; Thalhammer, F | 1 |
| Gerull, S; Gwerder, M; Halter, J; Heim, D; Hirsch, HH; Khanna, N; Lengerke, C; Leuzinger, K; Medinger, M; Passweg, J; Studer, U; Tsakiris, DA | 1 |
| Abramova, R; Assal, A; Bansal, R; Gordillo, CA; Mapara, MY; Pereira, MR; Reshef, R | 1 |
| Akashi, K; Aoki, T; Eto, T; Harada, T; Henzan, H; Ito, Y; Jinnouchi, F; Kadowaki, M; Kamimura, T; Kato, K; Kohno, K; Kuriyama, T; Miyamoto, T; Mori, Y; Nagafuji, K; Odawara, J; Ogawa, R; Ohno, Y; Takase, K; Takenaka, K; Ueno, T; Yoshimoto, G | 1 |
| Dodd, B; Hamadeh, I; Kachur, E; Roshdy, D; Shahid, Z | 1 |
| Imlay, HN; Kaul, DR | 1 |
| Bittel, P; Dahdal, S; Hirzel, C; Hofmann, E; Manuel, O; Sidler, D; Suter-Riniker, F; Walti, LN | 1 |
| Derigs, P; Dreger, P; Hegenbart, U; Luft, T; Müller-Tidow, C; Radujkovic, A; Schmitt, M; Schnitzler, P; Schöning, T; Schönland, SO; Schubert, ML | 1 |
| Cho, CR; Davis, C; de Alwis, D; Dykstra, K; Fancourt, C; Iwamoto, M; Macha, S; Prohn, M; Sabato, P; Viberg, A; Zhang, D | 1 |
| Brown, A; Gupta, G; Kumar, D; Song, C; Thacker, L; Winstead, RJ; Yakubu, I | 1 |
| Chu, X; Kothare, P; Kropeit, D; McCrea, JB; Menzel, K | 1 |
| Akoto, B; Boeckh, M; De Rosa, SC; Duke, ER; Edmison, BC; Finak, G; Jerome, KR; Kiener, R; Leisenring, WM; Mielcarek, M; Schiffer, JT; Stevens-Ayers, T; Wagner, R; Xie, H; Zamora, D | 1 |
| D'Addona, M; Ferrara, I; Fontana, R; Giudice, V; Guariglia, R; Langella, M; Martorelli, MC; Mettivier, L; Pezzullo, L; Selleri, C; Serio, B; Vaccaro, E | 1 |
| Doke, Y; Fukuda, T; Fukushi, Y; Hashimoto, H; Inamoto, Y; Nakashima, T; Yamaguchi, M | 1 |
| Gruber, J; Ingemi, AI; Khardori, N; McMahon, M; Pearston, AP; Ripley, K; Sutton, S; Wilson, TJ | 1 |
| Chalandon, Y; Masouridi-Levrat, S; Neofytos, D; Royston, E; Royston, L; Van Delden, C | 1 |
| Barton, J; Behr, J; Kauke, T; Keppler, OT; Kneidinger, N; Meiser, B; Michel, S; Milger, K; Munker, D; Nitschko, H; Veit, T; Zoller, M | 1 |
| Müller, TF; Näf, B; Rho, E; Schachter, T; von Moos, S; Wüthrich, RP | 1 |
| Schleiss, MR | 1 |
| Avery, R; Clark, NM; Gonzalez, AA; Hakki, M; Kaul, DR; Kotton, CN; Kovacs, C; La Hoz, RM; Limaye, AP; Linder, KA; Malinis, M; Mishkin, A; Mullane, KM; Ostrander, D; Prono, MD; Smith, J; Wolfe, C | 1 |
| Descourouez, JL; Garg, N; Jorgenson, MR; Mandelbrot, DA; Odorico, JS; Parajuli, S; Saddler, CM; Smith, JA | 1 |
| Boeckh, M; Dahlberg, A; Delaney, C; Hill, JA; Leisenring, WM; Milano, F; Pergam, SA; Thur, LA; Xie, H; Zamora, D | 1 |
| Alain, S; Baumert, TF; Gourin, C; Hantz, S; Ligat, G; Muller, C | 1 |
| Einsele, H; Fuji, S; Kapp, M | 1 |
| Erb-Zohar, K; Kobalava, ZD; Kropeit, D; McCormick, D; Moiseev, VS; Rübsamen-Schaeff, H; Stobernack, HP; Zimmermann, H | 1 |
| Chou, S | 1 |
| Badshah, C; Blumberg, EA; Boeckh, M; Brown, J; Chemaly, RF; Dadwal, SS; DiNubile, MJ; Duarte, RF; Einsele, H; Haider, S; Kanda, Y; Kartsonis, NA; Katayama, Y; Leavitt, RY; Ljungman, P; Maertens, J; Marty, FM; Mullane, KM; Murata, Y; Snydman, DR; Teal, VL; Ullmann, AJ; Wan, H | 1 |
| Clark, AE; Gordts, PLSM; Sabalza, M; Spector, DH | 1 |
| Kim, ES | 1 |
| Badshah, C; Maertens, J; Marty, FM | 1 |
| Humar, A; Kumar, D; L’Huillier, AG | 1 |
| Mori, J; Oshima, K; Tanimoto, T | 1 |
| Gentile, G; Micozzi, A | 1 |
| Frange, P; Leruez-Ville, M | 1 |
| Razonable, RR | 1 |
| Gagelmann, N; Kröger, N; Ljungman, P; Styczynski, J | 1 |
| Chen, D; Cho, CR; Hartmann, G; Menzel, K; Wang, YH | 1 |
| Chou, S; Ercolani, RJ; Satterwhite, LE | 1 |
| Geswein, L | 1 |
| Meesing, A; Razonable, RR | 2 |
| Arasaratnam, RJ; Chong, PP; Drazner, MH; Garg, S; Peltz, M; Prokesch, BC; Teiber, D | 1 |
| Cho, JC; Le, AD; Locke, SC | 1 |
| Aitken, SL; Chemaly, RF; Foolad, F | 1 |
| Bogner, E; Drach, JC; Gentry, BG | 1 |
| Deleenheer, B; Maertens, J; Spriet, I | 1 |
| Dadwal, SS | 1 |
| Calcoen, B; Hecke, SV; Lagrou, K; Maertens, J | 1 |
| Boivin, G; Piret, J | 1 |
| Sinkó, J | 1 |
| Jung, S; Michel, D; Michel, M; Stamminger, T | 1 |
| Benesch, M; Donnerer, J; Kubesch, K; Lackner, H; Schwinger, W; Sperl, D; Strenger, V; Zach, K | 1 |
| Papanicolaou, GA; Perales, MA | 1 |
| Badshah, C; Butterton, JR; Chemaly, RF; Kartsonis, NA; Leavitt, RY; Ljungman, P; Maertens, J; Marty, FM; Murata, Y; Sarratt, K; Schmitt, M; Teal, VL; Wan, H | 1 |
| Andre, P; Asner, SA; Buclin, T; Decosterd, LA; Gengler, C; Jaton-Ogay, K; Mercier, T; Meylan, P; Murray, K; Natterer, J; Opota, O; Pérez Marín, M; Perez, MH; Rizzi, M | 1 |
| Kotton, CN | 1 |
| Becken, B; Chang, YC; Kilgore, JT; Lugo, D; Parikh, S; Prasad, V; Varga, MG | 1 |
| Arnold, P; Barton, J; Behr, J; Ceelen, F; Kauke, T; Kneidinger, N; Michel, S; Milger, K; Munker, D; Schiopu, S; Veit, T; Zoller, M | 1 |
| Arns, W; Beelen, DW; Budde, K; Dürr, M; Fischereder, M; Gwinner, W; Hummel, J; Lischka, P; Michel, D; Mühlfeld, A; Renders, L; Rübsamen-Schaeff, H; Stangl, M; Stoelben, S; Suwelack, B; Witzke, O; Zimmermann, H | 1 |
| Peggs, KS; Sellar, RS | 1 |
| Bornhäuser, M; Brown, J; Champlin, RE; Chemaly, RF; Ehninger, G; Einsele, H; Groth, C; Kölling, K; Lischka, P; Mullane, KM; Nowak, H; Richard, MP; Rübsamen-Schaeff, H; Silverman, M; Stobernack, HP; Stoelben, S; Ullmann, AJ; Zimmermann, H | 1 |
| Emery, VC; Griffiths, PD | 1 |
| Deluca, KA; Jaskoll, T; Melnick, M | 1 |
| Chemaly, RF; Ehninger, G; Ullmann, AJ | 1 |
| DiPersio, JF; Romee, R | 1 |
| Griffiths, P; Lumley, S | 1 |
| Boeckh, M; Murphy, WJ; Peggs, KS | 1 |
| Goldner, T; Lischka, P; Zimmermann, H | 1 |
| Lischka, P; Michel, D; Zimmermann, H | 1 |
| Holder, D; Lischka, P; Zhang, D; Zimmermann, H | 1 |
| Gerna, G; Lilleri, D | 1 |
| Bowman, LJ; Brennan, DC; Melaragno, JI | 1 |
| Baumeister, J; Goldner, T; Hewlett, G; Lischka, P; Paulsen, D; Ruebsamen-Schaeff, H; Wunberg, T; Zimmermann, H | 1 |
| Lischka, P; Marschall, M; Ruebsamen-Schaeff, H; Stamminger, T; Urban, A; Wildum, S; Zimmermann, H | 1 |
| Beatrix, O; Dumortier, J; Lapalus, MG; Lombard-Bohas, C; Scoazec, JY; Villarejo, J; Vochelle, V | 1 |
| Abele, S; Anderson, J; Auerochs, S; Choi, Y; Eickhoff, J; Ensminger, S; Klebl, B; Leis, M; Marschall, M; Michel, D; Rawlinson, W; Rechter, S; Schleiss, M; Scott, G; Stamminger, T | 1 |
| Nightingale, SL; Young, FE | 1 |
23 review(s) available for quinazolines and Cytomegalic Inclusion Disease
| Article | Year |
|---|---|
[Management of cytomegalovirus infection after hematopoietic stem cell transplantation].
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Quinazolines | 2019 |
[Antiviral prophylaxis for CMV, HSV/VZV and HBV in allogeneic hematopoietic cell transplantation in adult patients: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Topics: Acetates; Adult; Allografts; Antiviral Agents; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Hepatitis B; Herpes Simplex; Herpes Zoster; Humans; Quinazolines; Transplantation Conditioning | 2020 |
Advances in the Development of Therapeutics for Cytomegalovirus Infections.
Topics: Acetates; Antiviral Agents; Biomarkers; Clinical Studies as Topic; Cytomegalovirus; Cytomegalovirus Infections; Drug Development; Drug Resistance, Viral; Humans; Infectious Disease Transmission, Vertical; Quinazolines; Research Design; Sirtuins; Stem Cell Transplantation; Treatment Outcome; Viral Load | 2020 |
Cytomegalovirus disease in hematopoietic stem cell transplant patients: current and future therapeutic options.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Opportunistic Infections; Postoperative Complications; Quinazolines; Transplant Recipients | 2017 |
Letermovir: First Global Approval.
Topics: Acetates; Administration, Intravenous; Administration, Oral; Antiviral Agents; Canada; Cytomegalovirus; Cytomegalovirus Infections; Dose-Response Relationship, Drug; Drug Approval; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines; Treatment Outcome; United States | 2018 |
Maribavir, brincidofovir and letermovir: Efficacy and safety of new antiviral drugs for treating cytomegalovirus infections.
Topics: Acetates; Antiviral Agents; Benzimidazoles; Cytomegalovirus Infections; Cytosine; Ganciclovir; Humans; Organophosphonates; Quinazolines; Ribonucleosides | 2018 |
Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance; Hematopoietic Stem Cell Transplantation; Humans; Premedication; Quinazolines; Transplantation, Homologous | 2018 |
Comparative Efficacy and Safety of Different Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.
Topics: Acetates; Acyclovir; Allografts; Antiviral Agents; Benzimidazoles; Cytomegalovirus; Cytomegalovirus Infections; Female; Ganciclovir; Hematopoietic Stem Cell Transplantation; Humans; Male; Quinazolines; Ribonucleosides; Risk Factors; Valacyclovir | 2018 |
New Developments in the Management of Cytomegalovirus Infection After Transplantation.
Topics: Acetates; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Foscarnet; Ganciclovir; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Organ Transplantation; Quinazolines; Valganciclovir | 2018 |
Letermovir for prophylaxis of cytomegalovirus in allogeneic hematopoietic stem cell recipients.
Topics: Acetates; Antiviral Agents; Creatinine; Cytomegalovirus Infections; Drug Interactions; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines | 2018 |
Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients.
Topics: Acetates; Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines; Serologic Tests; Virus Activation | 2018 |
Pharmacologic and immunologic management of cytomegalovirus infection after solid organ and hematopoietic stem cell transplantation.
Topics: Acetates; Antiviral Agents; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Opportunistic Infections; Organ Transplantation; Quinazolines; Viral Load | 2018 |
Targeting the terminase: An important step forward in the treatment and prophylaxis of human cytomegalovirus infections.
Topics: Acetates; Animals; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus; Cytomegalovirus Infections; Endodeoxyribonucleases; Humans; Quinazolines; Viral Proteins; Virus Replication | 2019 |
Pharmacokinetic drug evaluation of letermovir prophylaxis for cytomegalovirus in hematopoietic stem cell transplantation.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Interactions; Drug Resistance, Viral; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines | 2018 |
Update on prevention of cytomegalovirus in hematopoietic cell transplantation.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines | 2019 |
Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.
Topics: Acetates; Animals; Antiviral Agents; Benzimidazoles; Clinical Trials as Topic; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Drug Development; Drug Resistance, Viral; Humans; Quinazolines; Ribonucleosides; Viral Proteins; Virus Replication | 2019 |
[Current treatment modalities of immunocompromised patients with cytomegalovirus infection. II. Therapeutic options and management strategies].
Topics: Acetates; Acyclovir; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans; Immunocompromised Host; Quinazolines; Stem Cell Transplantation | 2019 |
A Fine Balance: Using Letermovir for Salvage Antiviral Treatment While Preserving Efficacy.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Graft Rejection; Humans; Organ Transplantation; Quinazolines; Transplant Recipients; Treatment Outcome | 2020 |
Therapeutic strategies for cytomegalovirus infection in haematopoietic transplant recipients: a focused update.
Topics: Acetates; Antiviral Agents; Benzimidazoles; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Organophosphonates; Quinazolines; Ribonucleosides; T-Lymphocytes; Transplant Recipients; Transplantation, Homologous | 2014 |
Cytomegalovirus.
Topics: Acetates; Antiviral Agents; Benzimidazoles; Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Disease Transmission, Infectious; Double-Blind Method; Female; Ganciclovir; Humans; Male; Organ Transplantation; Organophosphonates; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Infectious; Quinazolines; Randomized Controlled Trials as Topic; Ribonucleosides | 2014 |
Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies.
Topics: Acetates; Adoptive Transfer; Animals; Antiviral Agents; Benzimidazoles; Cell- and Tissue-Based Therapy; Clinical Trials, Phase III as Topic; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Hematopoietic Stem Cell Transplantation; Humans; Isoxazoles; Killer Cells, Natural; Leflunomide; Mice; Organophosphonates; Quinazolines; Ribonucleosides; T-Lymphocytes | 2015 |
Strategies to control human cytomegalovirus infection in adult hematopoietic stem cell transplant recipients.
Topics: Acetates; Adult; Animals; Antiviral Agents; Asymptomatic Diseases; Benzimidazoles; Clinical Trials as Topic; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Disease Management; Gastroenteritis; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Monitoring, Immunologic; Organophosphonates; Pneumonia; Postoperative Complications; Quinazolines; Ribonucleosides | 2016 |
Letermovir for the management of cytomegalovirus infection.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Design; Drug Resistance, Viral; Humans; Immunocompromised Host; Quinazolines | 2017 |
10 trial(s) available for quinazolines and Cytomegalic Inclusion Disease
| Article | Year |
|---|---|
Exposure-Response Analyses of Letermovir Following Oral and Intravenous Administration in Allogeneic Hematopoietic Cell Transplantation Recipients.
Topics: Acetates; Administration, Intravenous; Administration, Oral; Adolescent; Adult; Aged; Antiviral Agents; Cytomegalovirus Infections; Dose-Response Relationship, Drug; Double-Blind Method; Drug Dosage Calculations; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Models, Biological; Quinazolines; Transplantation, Homologous; Treatment Outcome; Young Adult | 2022 |
Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation.
Topics: Acetates; Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; DNA; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines; Random Allocation | 2020 |
Population pharmacokinetics of letermovir following oral and intravenous administration in healthy participants and allogeneic hematopoietic cell transplantation recipients.
Topics: Acetates; Administration, Intravenous; Administration, Oral; Adult; Aged; Antiviral Agents; Biological Availability; Case-Control Studies; Cytomegalovirus Infections; Dose-Response Relationship, Drug; Double-Blind Method; Female; Healthy Volunteers; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Pharmacogenetics; Placebos; Quinazolines; Transplant Recipients | 2021 |
Drug interaction between letermovir and voriconazole after allogeneic hematopoietic cell transplantation.
Topics: Acetates; Adult; Aged; Allografts; Cytomegalovirus; Cytomegalovirus Infections; Drug Interactions; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Quinazolines; Retrospective Studies; Voriconazole | 2021 |
Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment.
Topics: Acetates; Administration, Oral; Adolescent; Adult; Aged; Antiviral Agents; Area Under Curve; Cytomegalovirus Infections; Drug Administration Schedule; Female; Half-Life; Humans; Liver; Liver Diseases; Metabolic Clearance Rate; Middle Aged; Quinazolines; Russia; Severity of Illness Index; Treatment Outcome; Young Adult | 2017 |
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.
Topics: Acetates; Adolescent; Adult; Aged; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Double-Blind Method; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Quinazolines; Young Adult | 2017 |
A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines | 2020 |
Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study.
Topics: Acetates; Adult; Aged; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Female; Humans; Kidney Transplantation; Male; Middle Aged; Opportunistic Infections; Quinazolines; Viral Load; Viremia | 2014 |
Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation.
Topics: Acetates; Adult; Antiviral Agents; Cytomegalovirus Infections; Dose-Response Relationship, Drug; Double-Blind Method; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Incidence; Kaplan-Meier Estimate; Opportunistic Infections; Quinazolines; Transplantation, Homologous; Treatment Failure | 2014 |
Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228).
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Drug Resistance, Viral; Humans; Open Reading Frames; Quinazolines; Viral Load; Viremia | 2016 |
86 other study(ies) available for quinazolines and Cytomegalic Inclusion Disease
| Article | Year |
|---|---|
Emergence of Letermovir-resistant HCMV UL56 mutant during rescue treatment in a liver transplant recipient with ganciclovir-resistant infection HCMV: a case report.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Ganciclovir; Humans; Liver Transplantation; Mutation; Neoplasm Recurrence, Local; Quinazolines | 2021 |
Letermovir prophylaxis in T-cell-depleted transplants: breakthrough and rebound infections in the postmarketing setting.
Topics: Acetates; Cytomegalovirus; Cytomegalovirus Infections; Humans; Quinazolines; T-Lymphocytes | 2021 |
Letermovir treatment for CMV infection in kidney and pancreas transplantation: A valuable option for complicated cases.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Ganciclovir; Humans; Kidney; Kidney Transplantation; Leukopenia; Pancreas Transplantation; Quinazolines | 2022 |
Letermovir conversion after valganciclovir treatment in cytomegalovirus high-risk abdominal solid organ transplant recipients may promote development of cytomegalovirus-specific cell mediated immunity.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Ganciclovir; Humans; Immunity, Cellular; Kidney Transplantation; Male; Quinazolines; Transplant Recipients; Valganciclovir | 2022 |
Impact of Letermovir Primary Cytomegalovirus Prophylaxis on 1-Year Mortality After Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort Study.
Topics: Acetates; Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines; Retrospective Studies | 2022 |
Letermovir and maribavir for pan-resistant cytomegalovirus infection in a patient with haematologic malignancy: Consideration for combination therapy.
Topics: Acetates; Adult; Antiviral Agents; Benzimidazoles; Cytomegalovirus; Cytomegalovirus Infections; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Quinazolines; Ribonucleosides | 2022 |
Cytomegalovirus prevention in thoracic organ transplantation: A single-center evaluation of letermovir prophylaxis.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Organ Transplantation; Quinazolines; Retrospective Studies; Transplant Recipients | 2022 |
Human Cytomegalovirus-Specific T-Cell Reconstitution and Late-Onset Cytomegalovirus Infection in Hematopoietic Stem Cell Transplantation Recipients following Letermovir Prophylaxis.
Topics: Acetates; Cytomegalovirus; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Neoplasm Recurrence, Local; Prospective Studies; Quinazolines | 2022 |
Effective Letermovir Prophylaxis of CMV infection post allogeneic hematopoietic cell transplantation: Results from the French temporary authorization of use compassionate program.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Quinazolines | 2022 |
Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamide.
Topics: Acetates; Adult; Cyclophosphamide; Cytomegalovirus; Cytomegalovirus Infections; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines; Retrospective Studies; Unrelated Donors; Valacyclovir | 2022 |
Reliable quantification of Cytomegalovirus DNAemia in Letermovir treated patients.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Deoxyribonucleases; DNA, Viral; Ganciclovir; Humans; Quinazolines | 2022 |
Letermovir for Cytomegalovirus Prevention in Adolescent Patients Following Hematopoietic Cell Transplantation.
Topics: Acetates; Adolescent; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines | 2022 |
In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Ganciclovir; Humans; Mutation; Phenotype; Quinazolines | 2022 |
Risk factors for late cytomegalovirus infection after completing letermovir prophylaxis.
Topics: Acetates; Antiviral Agents; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines; Retrospective Studies; Risk Factors | 2022 |
Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality.
Topics: Acetates; Cytomegalovirus; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin G; Quinazolines; Retrospective Studies; Stem Cell Transplantation; Transplantation, Homologous | 2022 |
Real-world efficacy of letermovir prophylaxis for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation: A single-center retrospective analysis.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines; Retrospective Studies | 2022 |
Letermovir Prophylaxis for Cytomegalovirus Infection in Children After Hematopoietic Cell Transplantation.
Topics: Acetates; Adult; Child; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines; Retrospective Studies | 2022 |
Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Humans; Mutation; Quinazolines | 2022 |
Cytomegalovirus breakthrough and resistance during letermovir prophylaxis.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines | 2023 |
Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis After Kidney Transplant-Reply.
Topics: Acetates; Antiviral Agents; Chemoprevention; Cytomegalovirus; Cytomegalovirus Infections; Kidney Transplantation; Quinazolines; Valganciclovir | 2023 |
Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
Topics: Acetates; Adult; Aged; Antibiotic Prophylaxis; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Female; Graft Rejection; Heart Transplantation; Humans; Immunosuppressive Agents; Lung Transplantation; Male; Middle Aged; Quinazolines; Secondary Prevention; Transplant Recipients; Treatment Outcome | 2019 |
Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience.
Topics: Acetates; Adult; Aged; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Quinazolines; Retrospective Studies; Secondary Prevention; Transplantation, Homologous; Treatment Outcome; Viral Load; Virus Activation; Young Adult | 2019 |
Letermovir for the Management of Cytomegalovirus-associated Uveitis.
Topics: Acetates; Adult; Aged; Antiviral Agents; Aqueous Humor; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Eye Infections, Viral; Female; Follow-Up Studies; Humans; Male; Middle Aged; Quinazolines; Retrospective Studies; Uveitis; Visual Acuity | 2021 |
Artemisone demonstrates synergistic antiviral activity in combination with approved and experimental drugs active against human cytomegalovirus.
Topics: Acetates; Antiviral Agents; Artemisinins; Benzimidazoles; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Interactions; Drug Synergism; Drugs, Investigational; Female; Ganciclovir; Humans; Organ Culture Techniques; Organophosphonates; Placenta; Pregnancy; Quinazolines; Ribonucleosides | 2019 |
Letermovir prophylaxis through day 100 post transplant is safe and effective compared with alternative CMV prophylaxis strategies following adult cord blood and haploidentical cord blood transplantation.
Topics: Acetates; Adult; Antiviral Agents; Cord Blood Stem Cell Transplantation; Cytomegalovirus Infections; Fetal Blood; Humans; Quinazolines | 2020 |
Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients.
Topics: Acetates; Antibiotic Prophylaxis; Antiviral Agents; Clinical Trials, Phase III as Topic; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Hematopoietic Stem Cell Transplantation; Humans; Mutation; Quinazolines; Randomized Controlled Trials as Topic | 2020 |
De Novo Genotypic Heterogeneity in the UL56 Region in Cytomegalovirus-Infected Tissues: Implications for Primary Letermovir Resistance.
Topics: Acetates; Aged; Aged, 80 and over; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Endodeoxyribonucleases; Female; Genetic Heterogeneity; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Mutation; Open Reading Frames; Quinazolines; Viral Structural Proteins | 2020 |
Letermovir (Prevymis) for CMV prophylaxis.
Topics: Acetates; Adult; Allografts; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines; Transplant Recipients | 2019 |
Letermovir as Salvage Therapy for Cytomegalovirus Infection in Transplant Recipients.
Topics: Acetates; Adult; Aged; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Organ Transplantation; Quinazolines; Retrospective Studies; Salvage Therapy; Transplant Recipients; Viral Load | 2020 |
Letermovir for Secondary Prophylaxis of Cytomegalovirus Infection and Disease after Allogeneic Hematopoietic Cell Transplantation: Results from the French Compassionate Program.
Topics: Acetates; Adult; Antiviral Agents; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Prospective Studies; Quinazolines; Retrospective Studies | 2020 |
Clinical "real-world" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
Topics: Acetates; Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines; Transplant Recipients | 2020 |
Placental transfer of Letermovir & Maribavir in the ex vivo human cotyledon perfusion model. New perspectives for in utero treatment of congenital cytomegalovirus infection.
Topics: Acetates; Adult; Antiviral Agents; Benzimidazoles; Chromatography, Liquid; Cytomegalovirus Infections; Female; Humans; Kinetics; Maternal-Fetal Exchange; Models, Biological; Perfusion; Placenta; Pregnancy; Quinazolines; Ribonucleosides; Tandem Mass Spectrometry | 2020 |
Letermovir breakthroughs during the French Named Patient Programme: interest of monitoring blood concentration in clinical practice.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Humans; Quinazolines | 2020 |
Letermovir Prophylaxis Decreases Burden of Cytomegalovirus (CMV) in Patients at High Risk for CMV Disease Following Hematopoietic Cell Transplant.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines; Retrospective Studies; Transplant Recipients | 2020 |
Combination Treatment With Letermovir and Ganciclovir for Maintenance Therapy of Multidrug-resistant CMV Infection in a Liver Transplant Recipient.
Topics: Acetates; Allografts; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Humans; Liver; Liver Transplantation; Maintenance Chemotherapy; Off-Label Use; Postoperative Care; Quinazolines; Treatment Outcome; Valganciclovir | 2020 |
Eosinophilia during letermovir treatment after allogeneic hematopoietic stem cell transplantation.
Topics: Acetates; Adult; Aged; Allografts; Antiviral Agents; Case-Control Studies; Cytomegalovirus Infections; Eosinophilia; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Quinazolines; Transplantation Conditioning | 2020 |
Cost-effectiveness analysis of cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients from a US payer perspective.
Topics: Acetates; Antiviral Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Cytomegalovirus; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines; Transplant Recipients; United States | 2021 |
Letermovir for the compassionate therapeutic use of cytomegalovirus infection.
Topics: Acetates; Aged; Antiviral Agents; Compassionate Use Trials; Cytomegalovirus; Cytomegalovirus Infections; Female; Humans; Male; Middle Aged; Quinazolines; Retrospective Studies; Treatment Outcome | 2021 |
Incidence of CMV Replication and the Role of Letermovir Primary/Secondary Prophylaxis in the Early Phase After Allogeneic Hematopoietic Stem Cell Transplantation - A Single Centre Study.
Topics: Acetates; Adult; Aged; Cytomegalovirus; Cytomegalovirus Infections; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Quinazolines; Transplantation, Homologous; Virus Replication | 2020 |
Extended letermovir administration, beyond day 100, is effective for CMV prophylaxis in patients with graft versus host disease.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines; Retrospective Studies | 2021 |
Efficacy of prophylactic letermovir for cytomegalovirus reactivation in hematopoietic cell transplantation: a multicenter real-world data.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines; Retrospective Studies | 2021 |
Single-center experience with use of letermovir for treatment of CMV infection in stem cell transplant recipients.
Topics: Acetates; Antiviral Agents; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines; Retrospective Studies; Transplant Recipients | 2021 |
Letermovir and Maribavir for the Treatment and Prevention of Cytomegalovirus Infection in Solid Organ and Stem Cell Transplant Recipients.
Topics: Acetates; Antiviral Agents; Benzimidazoles; Cytomegalovirus Infections; Drug Resistance, Viral; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines; Ribonucleosides; Transplant Recipients | 2021 |
Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Ganciclovir; Humans; Organ Transplantation; Quinazolines; Transplant Recipients | 2021 |
Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data.
Topics: Acetates; Adult; Aged; Antiviral Agents; Cohort Studies; Cytomegalovirus; Cytomegalovirus Infections; Female; Hematopoietic Stem Cell Transplantation; Humans; Latent Infection; Male; Middle Aged; Quinazolines; Transplantation, Homologous; Virus Activation; Young Adult | 2021 |
Letermovir prophylaxis in solid organ transplant-Assessing CMV breakthrough and tacrolimus drug interaction.
Topics: Acetates; Antiviral Agents; Cohort Studies; Cytomegalovirus; Cytomegalovirus Infections; Drug Interactions; Humans; Organ Transplantation; Quinazolines; Tacrolimus | 2021 |
Absorption, Metabolism, Distribution, and Excretion of Letermovir.
Topics: Acetates; Adult; Animals; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biotransformation; Cytochrome P-450 CYP3A; Cytomegalovirus; Cytomegalovirus Infections; Drug Elimination Routes; Drug Interactions; Glucuronosyltransferase; Healthy Volunteers; Hematopoietic Stem Cell Transplantation; Humans; Male; Medication Therapy Management; Neoplasm Proteins; Organic Anion Transporters; Quinazolines; Rats; Tissue Distribution | 2021 |
Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation.
Topics: Acetates; Adult; Aged; Cytomegalovirus; Cytomegalovirus Infections; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Linear Models; Lymphocyte Count; Male; Middle Aged; Multivariate Analysis; Phenotype; Quinazolines; T-Lymphocytes; Virus Activation; Young Adult | 2021 |
Prophylactic letermovir decreases cytomegalovirus reactivation after stem cell transplantation: a single-center real-world evidence study.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines; Transplant Recipients; Transplantation, Homologous | 2021 |
Successful Treatment of UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Viremia in a Renal Transplant Recipient With Letermovir and Adjunct Hyperimmune Cytomegalovirus Immunoglobulin: A Case Report.
Topics: Acetates; Antibodies, Viral; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Ganciclovir; Humans; Immunoglobulins, Intravenous; Kidney Transplantation; Male; Middle Aged; Mutation; Postoperative Complications; Quinazolines; Viral Load; Viremia | 2021 |
Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high-risk hematopoietic cell transplant recipients.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines; Retrospective Studies; Transplant Recipients | 2021 |
Letermovir in lung transplant recipients with cytomegalovirus infection: A retrospective observational study.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Hematopoietic Stem Cell Transplantation; Humans; Lung; Quinazolines; Retrospective Studies; Transplant Recipients | 2021 |
Use of letermovir-valganciclovir combination as a step-down treatment after foscarnet for ganciclovir-resistant CMV infection in kidney transplant recipients.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans; Kidney Transplantation; Quinazolines; Transplant Recipients; Valganciclovir | 2021 |
Letermovir and HCT: too much of a good thing?
Topics: Acetates; Cytomegalovirus; Cytomegalovirus Infections; Humans; Quinazolines | 2021 |
Letermovir treatment of cytomegalovirus infection or disease in solid organ and hematopoietic cell transplant recipients.
Topics: Acetates; Antiviral Agents; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines; Transplant Recipients; Viral Load | 2021 |
The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients.
Topics: Acetates; Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Ganciclovir; Humans; Kidney Transplantation; Quinazolines; Transplant Recipients; Valganciclovir; Viremia | 2021 |
Delayed-onset cytomegalovirus infection is frequent after discontinuing letermovir in cord blood transplant recipients.
Topics: Acetates; Antiviral Agents; Cord Blood Stem Cell Transplantation; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines | 2021 |
New Insights into Human Cytomegalovirus pUL52 Structure.
Topics: Acetates; Amino Acid Motifs; Antiviral Agents; Conserved Sequence; Cytomegalovirus; Cytomegalovirus Infections; Endodeoxyribonucleases; Humans; Quinazolines; Viral Proteins; Virus Replication | 2021 |
A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance.
Topics: Acetates; Antiviral Agents; Cells, Cultured; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Endodeoxyribonucleases; Fibroblasts; Genes, Viral; Humans; Multiprotein Complexes; Mutation; Quinazolines; Viral Proteins | 2017 |
Human Cytomegalovirus Replication Is Inhibited by the Autophagy-Inducing Compounds Trehalose and SMER28 through Distinctively Different Mechanisms.
Topics: Allyl Compounds; Antiviral Agents; Autophagy; Cell Line; Cytomegalovirus; Cytomegalovirus Infections; Humans; Quinazolines; rab GTP-Binding Proteins; rab7 GTP-Binding Proteins; Trehalose; Virus Replication | 2018 |
Letermovir Prophylaxis for Cytomegalovirus.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Ganciclovir; Humans; Quinazolines | 2018 |
Letermovir Prophylaxis for Cytomegalovirus.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Ganciclovir; Humans; Quinazolines | 2018 |
Letermovir Prophylaxis for Cytomegalovirus.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Ganciclovir; Humans; Quinazolines | 2018 |
Letermovir Prophylaxis for Cytomegalovirus.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Ganciclovir; Humans; Quinazolines | 2018 |
PBPK Modeling Strategy for Predicting Complex Drug Interactions of Letermovir as a Perpetrator in Support of Product Labeling.
Topics: Acetates; Adult; Antiviral Agents; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytomegalovirus Infections; Drug Interactions; Drug Labeling; Female; Hematopoietic Stem Cell Transplantation; Humans; Hypnotics and Sedatives; Liver-Specific Organic Anion Transporter 1; Male; Midazolam; Models, Biological; Quinazolines; Young Adult | 2019 |
New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by
Topics: Acetates; Amino Acid Substitution; Antiviral Agents; Cell Line; Cytomegalovirus; Cytomegalovirus Infections; DNA-Directed DNA Polymerase; Drug Resistance, Viral; Endodeoxyribonucleases; Ganciclovir; Humans; Mutation; Quinazolines; Viral Structural Proteins | 2018 |
Letermovir associated hepatic transaminitis: A case report.
Topics: Acetates; Adult; Antiviral Agents; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Liver; Male; Quinazolines | 2019 |
Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation).
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Ganciclovir; Heart Transplantation; Humans; Male; Middle Aged; Mutation; Phosphotransferases (Alcohol Group Acceptor); Quinazolines; Secondary Prevention; Treatment Outcome | 2018 |
Letermovir for prophylaxis of cytomegalovirus manifestations in adult allogeneic hematopoietic stem cell transplant recipients.
Topics: Acetates; Adult; Antibiotic Prophylaxis; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Evaluation; Drug Interactions; Drug Resistance, Viral; Endodeoxyribonucleases; Hematopoietic Stem Cell Transplantation; Humans; Nucleic Acid Synthesis Inhibitors; Quinazolines; Transplant Recipients; Treatment Outcome | 2019 |
Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
Topics: Acetates; Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; DNA-Directed DNA Polymerase; Drug Resistance, Viral; Hematopoietic Stem Cell Transplantation; Humans; Male; Mutation; Quinazolines; Secondary Prevention; Valganciclovir; Viral Load; Viral Proteins; Viral Structural Proteins | 2019 |
Letermovir in paediatric HSCT recipients.
Topics: Acetates; Antiviral Agents; Child; Cytomegalovirus Infections; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Liver Diseases; Quinazolines; Transplant Recipients | 2019 |
Cytomegalovirus Viremia and Death After Hematopoietic Cell Transplantation: More Complex Than "To Have and Have Not"?
Topics: Acetates; Cytomegalovirus; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines; Viremia | 2020 |
Compassionate Use of Letermovir in a 2-Year-Old Immunocompromised Child With Resistant Cytomegalovirus Disease.
Topics: Acetates; Antiviral Agents; Child, Preschool; Compassionate Use Trials; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Dose-Response Relationship, Drug; Drug Monitoring; Extracorporeal Membrane Oxygenation; Fatal Outcome; Female; Ganciclovir; Hepatitis, Viral, Human; Humans; Immunocompromised Host; Opportunistic Infections; Pneumonia, Viral; Polymerase Chain Reaction; Quinazolines; Treatment Failure; Viral Load | 2020 |
Use of Letermovir for Salvage Therapy for Resistant Cytomegalovirus in a Pediatric Hematopoietic Stem Cell Transplant Recipient.
Topics: Acetates; Adolescent; Antiviral Agents; Cytomegalovirus Infections; Drug Resistance, Viral; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Quinazolines; Salvage Therapy | 2020 |
Letermovir for Difficult to Treat Cytomegalovirus Infection in Lung Transplant Recipients.
Topics: Acetates; Adult; Aged; Antibodies, Viral; Cytomegalovirus; Cytomegalovirus Infections; Female; Graft Rejection; Humans; Lung Transplantation; Male; Middle Aged; Quinazolines; Transplant Recipients | 2020 |
Taming the transplantation troll by targeting terminase.
Topics: Acetates; Antiviral Agents; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Opportunistic Infections; Quinazolines | 2014 |
CMV-induced pathology: pathway and gene-gene interaction analysis.
Topics: Animals; Carcinoma, Mucoepidermoid; Cytomegalovirus; Cytomegalovirus Infections; Epistasis, Genetic; Female; Gefitinib; Gene Expression Regulation; Gene Regulatory Networks; Humans; Mice; Mice, Inbred C57BL; Models, Theoretical; Organ Culture Techniques; Protein Kinase Inhibitors; Quinazolines; Salivary Gland Neoplasms; Salivary Glands; Signal Transduction; Tumor Microenvironment | 2014 |
CMV prophylaxis in hematopoietic-cell transplantation.
Topics: Acetates; Antiviral Agents; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Opportunistic Infections; Quinazolines | 2014 |
CMV prophylaxis in hematopoietic-cell transplantation.
Topics: Acetates; Antiviral Agents; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Opportunistic Infections; Quinazolines | 2014 |
Phenotypic characterization of two naturally occurring human Cytomegalovirus sequence polymorphisms located in a distinct region of ORF UL56 known to be involved in in vitro resistance to letermovir.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Genotype; Hematopoietic Stem Cell Transplantation; Humans; Mutation; Open Reading Frames; Phenotype; Polymorphism, Genetic; Quinazolines; Viral Structural Proteins | 2015 |
Impact of glycoprotein B genotype and naturally occurring ORF UL56 polymorphisms upon susceptibility of clinical human cytomegalovirus isolates to letermovir.
Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Ganciclovir; Genotype; Humans; Microbial Sensitivity Tests; Mutation; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Quinazolines; Viral Envelope Proteins; Viral Structural Proteins | 2016 |
In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246.
Topics: Acetic Acid; Animals; Antiviral Agents; Cell Line; Cells, Cultured; Cytomegalovirus; Cytomegalovirus Infections; Cytopathogenic Effect, Viral; Dermis; Disease Models, Animal; Fibroblasts; Humans; Lung; Mice; Mice, SCID; Quinazolines; Transplantation, Heterologous; Treatment Outcome; Virus Replication | 2010 |
In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Herpesviridae; Humans; Microbial Sensitivity Tests; Quinazolines; Species Specificity; Virus Diseases; Viruses | 2012 |
[Severe acute cytomegalovirus colitis after administration of irinotecan and raltitrexed chemotherapy].
Topics: Acute Disease; Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Camptothecin; Colitis; Cytomegalovirus Infections; Ganciclovir; Humans; Immunocompromised Host; Irinotecan; Male; Quinazolines; Rectal Neoplasms; Sigmoid Neoplasms; Thiophenes | 2003 |
Protein kinase inhibitors of the quinazoline class exert anti-cytomegaloviral activity in vitro and in vivo.
Topics: Animals; Antiviral Agents; Cell Survival; Cells, Cultured; Cytomegalovirus; Cytomegalovirus Infections; Female; Guinea Pigs; Humans; Inhibitory Concentration 50; Male; Mice; Phosphotransferases; Protein Kinase Inhibitors; Quinazolines; Rats; Sequence Deletion; Viral Load; Viral Plaque Assay; Viral Proteins | 2008 |
FDA's newly designated treatment INDs.
Topics: Clinical Protocols; Cytomegalovirus; Cytomegalovirus Infections; Drug Combinations; Drug Therapy, Combination; Glucuronates; Humans; Immune Sera; Immunoglobulins; Immunoglobulins, Intravenous; Kidney Transplantation; Leucovorin; Pneumonia, Pneumocystis; Quinazolines; Trimetrexate; United States; United States Food and Drug Administration | 1988 |